Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma.
This phase I study compared pharmacokinetics and pharmacodynamics, and assessed safety and efficacy of intravenous and subcutaneous administration of bortezomib. Relapsed or refractory multiple myeloma patients were randomized to receive bortezomib by standard intravenous bolus (n=12) or subcutaneous injection (n=12) at the recommended dose and schedule (1.3 mg/m2, days 1, 4, 8, 11; eight 21-day cycles). Plasma bortezomib concentration and percent 20S proteasome inhibition were measured at multiple time points on days 1 and 11, cycle 1. Systemic bortezomib exposure was similar between arms. As expected, mean maximum plasma concentration was lower and took longer to reach following subcutaneous administration. Overall 20S proteasome inhibition was similar between arms. Safety profile and response rate for the subcutaneous arm did not appear inferior to the intravenous arm, with good local tolerance of subcutaneous injection. Based on these exploratory findings, subcutaneous administration offers an alternative option to intravenous injection (ClinicalTrials.gov identifier: NCT00291538).
Moreau
Philippe
P
Department of Hematology, University Hospital, Nantes, France. philippe.moreau@chu-nantes.fr
Coiteux
Valerie
V
Hulin
Cyrille
C
Leleu
Xavier
X
van de Velde
Helgi
H
Acharya
Milin
M
Harousseau
Jean-Luc
JL